116 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
38
SAR of amino pyrrolidines as potent and novel protein-protein interaction inhibitors of the PRC2 complex through EED binding.
Abbvie
48
Integrated Platform for Expedited Synthesis-Purification-Testing of Small Molecule Libraries.
Abbvie
2
Turning a Substrate Peptide into a Potent Inhibitor for the Histone Methyltransferase SETD8.
Abbvie
3
Synthesis and Pharmacology of (Pyridin-2-yl)methanol Derivatives as Novel and Selective Transient Receptor Potential Vanilloid 3 Antagonists.
Abbvie
11
Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2.
Abbvie
5
Optimization of ADME Properties for Sulfonamides Leading to the Discovery of a T-Type Calcium Channel Blocker, ABT-639.
Abbvie
18
Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.
Abbvie
32
Discovery of (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea (A-1165442): a temperature-neutral transient receptor potential vanilloid-1 (TRPV1) antagonist with analgesic efficacy.
Abbvie
22
Pyrimidine-based tricyclic molecules as potent and orally efficacious inhibitors of wee1 kinase.
Abbvie
16
Discovery and development of potent and selective inhibitors of histone methyltransferase g9a.
Abbvie
2
Synthesis and SAR of 4-aminocyclopentapyrrolidines as orally active N-type calcium channel inhibitors for inflammatory and neuropathic pain.
Abbvie
45
Validation, Key Pharmacophores, and X-ray Cocrystal Structures of Novel Biochemically and Cellularly Active WRN Inhibitors Derived from a DNA-Encoded Library Screen.
Abbvie
76
Discovery and Development of CFTR Modulators for the Treatment of Cystic Fibrosis.
Abbvie
34
Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with In Vivo Target Engagement.
Abbvie
6
Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Abbvie
1
The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia.
Abbvie
9
Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours.
AbbVie
18
Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Abbvie
49
Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Na
Abbvie
16
Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
Abbvie
24
Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.
Abbvie
11
Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.
Abbvie
13
Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-X
Abbvie
15
Discovery of 2-aminoisobutyric acid ethyl ester (AIBEE) phosphoramidate prodrugs for delivering nucleoside HCV NS5B polymerase inhibitors.
Abbvie
17
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis.
Abbvie
22
Hit-to-lead evaluation of a novel class of sphingosine 1-phosphate lyase inhibitors.
Abbvie
4
Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection.
Abbvie
1
Emerging Approaches for the Identification of Protein Targets of Small Molecules - A Practitioners' Perspective.
Abbvie
5
Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.
Abbvie
28
Discovery and optimization of novel constrained pyrrolopyridone BET family inhibitors.
Abbvie
25
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).
Abbvie
32
De Novo Design, Synthesis, and Biological Evaluation of 3,4-Disubstituted Pyrrolidine Sulfonamides as Potent and Selective Glycine Transporter 1 Competitive Inhibitors.
Abbvie
24
Discovery of Spiro Oxazolidinediones as Selective, Orally Bioavailable Inhibitors of p300/CBP Histone Acetyltransferases.
Abbvie
41
Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
Abbvie
48
SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
Abbvie
32
Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
Abbvie
24
Are We There Yet? Applying Thermodynamic and Kinetic Profiling on Embryonic Ectoderm Development (EED) Hit-to-Lead Program.
Abbvie
56
Aryl aminopyrimidines as dual MerTK and TYRO3 inhibitors and methods thereof
The University Of North Carolina at Chapel Hill
44
Disubstituted Pyrimidine Compounds for Ketohexokinase Inhibition
Centennial Therapeutics
9
THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER
National Cancer Center
2
ORALLY BIOAVAILABLE, BRAIN-PENETRANT COMPOUND WITH SELECTIVITY FOR THE CANNABINOID TYPE 2 RECEPTOR WITH POTENTIAL USE TOWARDS VISCERAL PAIN MANAGEMENT AND NEURODEGENERATIVE DISORDERS
University of Mississippi
1
Salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Galapagos
17
Method for preparing pyrrolo[3,2-D]pyrimidine compound, and intermediates thereof
Chia Tai Tianqing Pharmaceutical Group
12
2-amino-6-(difluoromethyl)-5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as BACE1 inhibitors
H. Lundbeck
27
Macrocyclic indole derivatives useful as hepatitis C virus inhibitors
Janssen Ireland
366
Compounds inhibiting leucine-rich repeat kinase enzyme activity
Merck Sharp & Dohme
4
Slowly on, Slowly off: Bisubstrate-Analogue Conjugates of 5-Iodotubercidin and Histone H3 Peptide Targeting Protein Kinase Haspin.
University of Tartu
15
Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities
Almirall
12
2,5-disubstituted-pyridyl nicotinic ligands, and methods of use thereof
Georgetown University
64
Substituted 3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-ones as protein kinase inhibitors
Nerviano Medical Sciences
4
Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.
University College London
43
Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives.
Bezmialem Vakif University
217
Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase
Fibrogen
105
Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Array Biopharma
8
Tranylcypromine derivatives as inhibitors of histone demethylases LSD1 and/or LSD2
Sapienza University of Rome
5
Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
Merck Sharp & Dohme
5
Role of the four conserved histidine residues in the amidotransferase domain of carbamoyl phosphate synthetase.
Texas A&M University
4
Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.
National Yang-Ming University
24
Synthesis and Biological Evaluation of N-aryl-4-aryl-1,3-Thiazole-2-Amine Derivatives as Direct 5-Lipoxygenase Inhibitors.
Korea Research Institute of Chemical Technology
11
Bile salt export pump (BSEP/ABCB11) can transport a nonbile acid substrate, pravastatin.
University of Tokyo
1
Pharmacological characterization of human S1P4 using a novel radioligand, [4,5-3H]-dihydrosphingosine-1-phosphate.
Schering-Plough Research Institute
25
Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines.
Harvard University
9
In vitro characterization of [3H]MethoxyPyEP, an mGluR5 selective radioligand.
Merck Research Laboratories
15
L-homocysteine sulfinic acid and other acidic homocysteine derivatives are potent and selective metabotropic glutamate receptor agonists.
Case Western Reserve University
9
5HT4(a) and 5-HT4(b) receptors have nearly identical pharmacology and are both expressed in human atrium and ventricle.
University of Oslo
102
Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.
Sri International
5
A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.
The University of Tokyo
3
YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
Yamanouchi Pharmaceutical
4
Structural combination of established 5-HT(2A) receptor ligands: new aspects of the binding mode.
University of Mainz
6
A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain.
Eli Lilly
6
Binding of selective antagonists to four muscarinic receptors (M1 to M4) in rat forebrain.
UniversitÉ
13
Carbonic anhydrase inhibitors: inhibition of cytosolic carbonic anhydrase isozymes II and VII with simple aromatic sulfonamides and some azo dyes.
Universita Degli Studi Di Firenze
18
Characteristics of 125I-iodocyanopindolol binding to beta-adrenergic and serotonin-1B receptors of rat brain: selectivity of beta-adrenergic agents.
Niigata College of Pharmacy
1
SDZ 205-557, a selective, surmountable antagonist for 5-HT4 receptors in the isolated guinea pig ileum.
Sandoz Pharma
20
Uncharged isocoumarin-based inhibitors of urokinase-type plasminogen activator.
University of New Mexico
30
Alpha-noradrenergic receptor binding in mammalian brain: differential labeling of agonist and antagonist states.
TBA